Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NPR3 | P17342 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377145 | 1.00 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL8943683 | 1.00 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL24374500 | 0.93 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL26945874 | 0.86 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL26946176 | 0.85 | KDM4E (0.53) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL24669337 | 0.85 | KDM4E (0.53) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL26946171 | 0.85 | KDM4E (0.53) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL24359845 | 0.84 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL22557757 | 0.84 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL22557755 | 0.84 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2022084747-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| US-20140357602-A1 | Combination Therapies For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2014-12-04 | — | — | US | disclosed |
| CN-102421424-A | Combination therapies for treating metabolic disorders | ERIC MAYOUX | 2012-04-18 | — | — | CN | disclosed |
| EP-2408441-A1 | COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS | Genmedica Therapeutics SL (ES) | 2012-01-25 | — | — | EP | disclosed |
| US-20100239552-A1 | Combination Therapies for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-23 | — | — | US | disclosed |
| WO-2010106083-A1 | COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | KDM4E 3937/4885MAPT 2373/4885THRB 1852/4885 |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | SERPINB1, KLKB1, MPO | KDM4E 3753/4885MAPT 1912/4885THRB 2068/4885 |
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | KDM4E 3937/4885MAPT 2373/4885THRB 1852/4885 |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | KDM4E 3753/4885MAPT 1912/4885THRB 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.